Dimethaid enters next phase of European Mutual Recognition Procedure
TORONTO, Feb. 19 /CNW/ - Dimethaid Research Inc. (TSX: DMX) has formally
submitted applications for regulatory approval of PENNSAID(R) in Belgium,
Denmark, France, Germany, Greece, Iceland, Ireland, Liechtenstein, the
Netherlands, Norway, Portugal, Spain and Sweden.
PENNSAID is the company's first patented product based on its
transcellular technology. The drug is a topical solution for treating pain,
stiffness and impaired physical function associated with osteoarthritis. An
estimated 37 million Europeans have the disease.
In September 2002, Dimethaid submitted an updated product dossier to the
United Kingdom's Medicines Control Agency (MCA). The MCA, acting as the
company's agent under the European Mutual Recognition Procedure, has now
completed and will file its own assessment report with each state.
PENNSAID has marketing approval in the U.K. and several European
countries. It has been granted an approvable letter in Canada, and it is
currently under review by the Food and Drug Administration in the United
States.
About Dimethaid Research Inc.
Dimethaid Research Inc. is a publicly traded, Canadian, pharmaceutical
company headquartered in Markham, Ontario, with manufacturing facilities in
Varennes, Québec and Wanzleben, Germany. The company develops and
commercializes targeted therapeutic drugs designed to produce minimal side
effects. Dimethaid's two technology platforms focus on transcellular drug
delivery and immune system regulation. Products have potential applications in
such areas as osteoarthritis, onychomycosis and HIV/AIDS. For more
information, please visit www.dimethaid.com
This release may contain forward-looking statements, subject to risks and
uncertainties beyond management's control. Actual results could differ
materially from those expressed here. Risk factors are discussed in the
Company's annual information form filed with the securities commissions in
each of the provinces of Canada. The Company undertakes no obligation to
revise forward-looking statements in light of future events.
%SEDAR: 00002418EB |
